Merit Medical Launches the TEMNO Elite™ Soft Tissue Biopsy System
September 27 2022 - 9:25AM
Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global
manufacturer and marketer of healthcare technology, today announced
U.S. commercial release of the TEMNO Elite™ Soft Tissue Biopsy
System, the latest addition to Merit’s comprehensive portfolio of
biopsy devices.
Indicated for use in various soft tissue locations—such as
liver, lung, lymph nodes, kidney, and other soft tissue suspect
lesions—the single-use device is the result of Merit’s ongoing
commitment to the advancement of biopsy procedures and complements
a broader portfolio, which includes the TEMNO™, Achieve®, and
Tru-Cut® families of devices.
Biopsies are routinely performed to remove and examine tissue to
assist with the diagnosis of disease. Adequate sample size and
quality are paramount for accurate diagnosis and treatment.
Designed to retrieve superior samples, the TEMNO Elite’s Total
Core™ Biopsy Technology obtains samples 72% larger than competitor
side-notch, semi-automatic devices.1
To provide clinicians with total procedure control, the device’s
industry-first Sample Assist™ feature simplifies tissue removal,
allowing clinicians to retrieve full samples with an easy slide of
a button. An optional, valved coaxial introducer enhances patient
safety by reducing the risk of air entry and fluid leakage,
particularly important during lung biopsy.2
“The sample quality of the TEMNO Elite is excellent,” said
Stuart Aronson, MD, diagnostic radiology specialist at Texas Health
Harris Methodist Hospital in Fort Worth, TX. “The cores are
noticeably and consistently larger than other devices. The valved
coaxial introducer reduces procedural steps and blood leakage and
helps to reduce the risk of pneumothorax and air embolism.”
Learn more about the TEMNO Elite Biopsy System.
“Merit is committed to helping physicians provide the best care
possible for their patients—and this includes the crucial step of
accurate diagnosis,” said Fred P. Lampropoulos, Merit Medical’s
Chairman and CEO. “The TEMNO Elite is the latest innovation in our
portfolio of soft tissue biopsy devices, and it highlights Merit’s
ability to understand clinician and patient needs and innovate and
deliver technologies that advance patient care. We are pleased to
continue our progress in improving diagnostic accuracy in pathology
labs across the nation.”
ABOUT MERIT MEDICAL Founded in 1987, Merit Medical Systems, Inc.
is engaged in the development, manufacture, and distribution of
proprietary disposable medical devices used in interventional,
diagnostic, and therapeutic procedures, particularly in cardiology,
radiology, oncology, critical care, and endoscopy. Merit serves
client hospitals worldwide with a domestic and international sales
force and clinical support team totaling in excess of 500
individuals. Merit employs approximately 6,500 people
worldwide.
TRADEMARKS Unless noted otherwise, trademarks and registered
trademarks used in this release are the property of Merit Medical
Systems, Inc. and its subsidiaries in the United States and other
jurisdictions.
CONTACTS
PR/Media Inquiries Sarah Comstock Merit
Medical +1-801-432-2864 | sarah.comstock@merit.com
INVESTOR INQUIRIES Mike Piccinino, CFA, IRC Westwicke
- ICR +1-443-213-0509 | mike.piccinino@westwicke.com
REFERENCES
- Internal testing with 18G. Data on
File. Marketing Claims for the TEMNO Elite Device (ECN147270).
- Internal Testing. Data on File.
Validated with data from Valved One-Step™ Centesis Catheter. See
product brochure (401273001/C, ECN99826).
Merit Medical Systems (NASDAQ:MMSI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Merit Medical Systems (NASDAQ:MMSI)
Historical Stock Chart
From Jul 2023 to Jul 2024